Otros idiomas CytoDyn Inc.

Acciones

Diferido OTC Markets Otros sitios de cotización 16:15:13 27/06/2024			Varia. Cinco días.	Varia. 1 de enero.
0,1495 ^USD	+3,01 %		+9,77 %	-23,33 %

30/05	Transcript : CytoDyn Inc. - Special Call
15/04	CytoDyn Inc. informa de los resultados del tercer trimestre y los nueve meses finalizados el 29 de febrero de 2024	CI

CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024	14:30
CytoDyn : Private Placement - Form 8-K	03/06
CytoDyn to Host Webcast to Provide Company Update	28/05
May 2024 Letter to Shareholders	16/05
CytoDyn Inc. announced that it has received $8.942 million in funding	03/05
CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	15/04
CytoDyn Announces FDA Has Lifted Clinical Hold	29/02
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma	01/02
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma	01/02
CytoDyn Inc. Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma	01/02
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO	29/01
Cytodyn Inc. Announces CFO Changes	29/01
CytoDyn Inc. Announces Appointment of Jacob Lalezari as CEO	29/01
Purcell & Lefkowitz LLP Announces Shareholder Investigation of CytoDyn Inc. (OTC: CYDY)	18/01
CytoDyn Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	16/01
CytoDyn Inc. announced a financing transaction	29/12
CytoDyn Announces Webcast to Provide Company Update	07/12
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO	21/11
CytoDyn Inc. Appoints Jacob Lalezari M.D. as Interim CEO	21/11
OPDP Comes Out Swinging With A Warning Letter On Unsubstantiated Efficacy	08/11

No hay resultados para esta búsqueda